The U.S. Food and Drug Administration (FDA) has lifted its hold on a late-stage trial for Novavax’s COVID-influenza ...

BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...

Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...

However, the updated Novavax booster does not yet seem to have an application before the TGA, so it is likely to be some time away for us in Australia. While it's great we have been able to update ...

The TGA says vaccination against COVID-19 is one ... Source: Getty / Christina House/Los Angeles Times While non-mRNA vaccines — like the Novavax COVID-19 vaccine — inject the protein into ...

In early pandemic days, Novavax (NASDAQ: NVAX) shares soared as investors bet on the company's ability to bring a coronavirus vaccine to market. But as the biotech fell behind in the race and ...

The Novavax jab, which was approved by the Therapeutic Goods Administration (TGA) in January, is available at GP clinics, community pharmacies and state-run vaccine hubs for people aged 18 and over.

Novavax reports Q3 2024 sales of $84.5 million, beating estimates, with a net loss of $121 million. EPS improves, FDA approves new vaccine, and revenue guidance is lowered. Vandana Singh FDA Gives ...

(Bloomberg) -- Novavax Inc. shares fell 19% after US regulators placed a hold on the company’s experimental vaccines because a study volunteer developed a serious nerve disorder. The pause appli ...

Novavax has been gearing up to launch a phase 3 trial of what may result in an important product: A combined flu and coronavirus vaccine. But the company now faces a roadblock, saying regulators ...